ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2019 and provided an update on the Company's recent developments.

Click here to see the full Press Release